COM:LYELL
Lyell Immunopharma, Inc.
- Stock
Last Close
0.92
22/11 21:00
Market Cap
402.80M
Beta: -
Volume Today
1.01M
Avg: -
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|
average inventory | ||||||
average payables | 6.12M - | 6.30M 2.97% | 3.56M 43.47% | 4.37M 22.60% | ||
average receivables | ||||||
book value per share | 1.93 - | 3.39 76.06% | 6.84 101.62% | 3.37 50.70% | ||
capex per share | -0.08 - | -0.24 220.81% | -0.48 98.23% | -0.10 79.61% | ||
capex to depreciation | -12.78 - | -11.99 6.16% | -4.81 59.90% | -1.35 71.98% | -0.13 90.15% | |
capex to operating cash flow | -0.41 - | 0.32 178.72% | 0.52 62.14% | 0.14 72.41% | 0.02 88.54% | |
capex to revenue | -24.42 - | -6.64 72.82% | -6.15 7.34% | -0.29 95.34% | -20.66 7,107.45% | |
cash per share | 2.06 - | 2.89 40.49% | 4.52 56.34% | 2.59 42.72% | ||
days of inventory on hand | ||||||
days payables outstanding | ||||||
days sales outstanding | ||||||
debt to assets | 0.05 - | 0.06 21.54% | 0.06 0.12% | 0.07 20.04% | 0.08 16.63% | |
debt to equity | 0.07 - | 0.08 12.84% | 0.07 3.98% | 0.08 11.39% | 0.10 18.70% | |
dividend yield | ||||||
earnings yield | -0.03 - | -0.06 63.73% | -0.27 388.88% | -0.01 97.96% | ||
enterprise value | 3.51B - | 3.49B 0.47% | 826.00M 76.34% | 801.52M 2.96% | -82.48M 110.29% | |
enterprise value over ebitda | -34.78 - | -16.81 51.67% | -5.02 70.17% | -4.85 3.19% | 0.39 107.95% | |
ev to operating cash flow | 88.85 - | -21.70 124.42% | -6.54 69.85% | -4.73 27.75% | 0.50 110.66% | |
ev to sales | 5.34K - | 450.05 91.57% | 77.56 82.77% | 9.46 87.80% | -634.46 6,803.31% | |
free cash flow per share | 0.11 - | -1.00 1,006.45% | -1.41 40.68% | -0.78 44.39% | ||
free cash flow yield | 0.01 - | -0.06 1,006.45% | -0.18 206.98% | -0.23 24.03% | ||
graham net net | 1.36 - | 2.00 46.56% | 3.07 53.72% | 2.17 29.34% | ||
graham number | 4.98 - | 8.46 69.79% | 17.98 112.53% | 1.21 93.28% | ||
income quality | -0.31 - | 0.79 357.87% | 0.50 35.87% | 0.93 83.52% | 0.70 24.65% | |
intangibles to total assets | 0 - | 0 | 0 | 0 | 0 | |
interest coverage | ||||||
interest debt per share | 0.13 - | 0.26 98.67% | 0.50 93.60% | 0.27 45.09% | ||
inventory turnover | ||||||
invested capital | 0.07 - | 0.08 12.84% | 0.07 3.98% | 0.08 11.39% | 0.10 18.70% | |
market cap | 3.58B - | 3.58B 0% | 1.05B 70.58% | 857.37M 18.50% | ||
net current asset value | 292.68M - | 427.71M 46.13% | 428.67M 0.22% | 546.99M 27.60% | 459.61M 15.97% | |
net debt to ebitda | 0.69 - | 0.41 39.77% | 1.37 231.96% | 0.34 75.35% | 0.39 14.02% | |
net income per share | -0.57 - | -0.94 63.73% | -2.10 124.03% | -0.02 99.08% | ||
operating cash flow per share | 0.19 - | -0.76 507.54% | -0.93 22.26% | -0.69 26.12% | ||
payables turnover | ||||||
receivables turnover | ||||||
research and ddevelopement to revenue | 96.80 - | 23.50 75.73% | 13.02 44.58% | 1.88 85.57% | 1.41K 74,762.29% | |
return on tangible assets | -0.22 - | -0.22 0.16% | -0.25 15.85% | -0.01 98.00% | -0.31 6,069.49% | |
revenue per share | 0.00 - | 0.04 1,080.52% | 0.08 113.92% | 0.34 337.41% | ||
roe | -0.30 - | -0.28 7.01% | -0.31 11.12% | -0.01 98.14% | -0.36 6,179.06% | |
roic | -0.21 - | -0.25 20.32% | -0.23 7.50% | -0.00 97.87% | -0.30 6,052.76% | |
sales general and administrative to revenue | 59.59 - | 6.04 89.86% | 8.36 38.34% | 1.39 83.43% | 515.25 37,095.77% | |
shareholders equity per share | 1.93 - | 3.39 76.06% | 6.84 101.62% | 3.37 50.70% | ||
stock based compensation to revenue | 23.95 - | 4.29 82.09% | 5.84 36.19% | 0.97 83.44% | 362.18 37,338.21% | |
tangible asset value | 408.06M - | 718.44M 76.06% | 929.79M 29.42% | 833.25M 10.38% | 654.95M 21.40% | |
tangible book value per share | 1.93 - | 3.39 76.06% | 6.84 101.62% | 3.37 50.70% | ||
working capital | 418.21M - | 568.26M 35.88% | 579.55M 1.99% | 614.27M 5.99% | 520.17M 15.32% |
All numbers in (except ratios and percentages)